Your Partner from Discovery to Therapeutic

Accelerate cancer research with innovative solutions

AACR 2022, New Orleans

April 8-13, Booth 2529

hero image

Exhibitor Spotlight Theater

MON 10:00 AM CST

The New QX600 Droplet Digital PCR System for Advanced Multiplexing ​

Monday, April 11
10:00 AM CST
Spotlight Theater D

In the past ten years, over 6,300 publications detailing important discoveries have been generated by researchers across many disciplines using Droplet Digital PCR (ddPCR). Now we are introducing a powerful addition to cancer biology research with industry leading performance plus 6-color multiplexing capabilities and the option of more partitions for enhanced dynamic range and sensitivity. These advancements will enable more breakthroughs across cancer research applications.


Pallavi Shah, PhD

Pallavi Shah, PhD

Staff Scientist
Bio-Rad Laboratories

Aki Uehara

Aki Uehara

Global Marketing Manager
Bio‑Rad Laboratories

Key Products

With over 70 years of expertise in genomics and proteomics, depend on Bio-Rad for tools and technologies to enable cancer research.

Droplet Digital PCR

Unrivaled accuracy and precision

A breakthrough technology for ultrasensitive absolute nucleic acid quantification. Droplet Digital PCR (ddPCR) is particularly useful for low-abundance targets and challenging samples, expanding your testing capabilities for precision monitoring of cancer biomarkers.

​Learn more​ ▸

QX600 Droplet Digital PCR


The newest advancement in ddPCR technology—expanded dynamic range, sensitivity and 6-color multiplexing.

Visit booth 2529 for an exclusive sneak peek!

Be the first to know! ▸

 Schedule a ddPCR Demo ▸

QX ONE Droplet Digital PCR System

Walk-away automation of the ddPCR workflow to deliver unrivaled precision with advanced multiplexing.

​Learn more​ ▸

QX200 AutoDG Droplet Digital PCR System

Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring. See how this ultra-sensitive and precise technology gives clinicians insights that can guide personalized cancer treatments and save lives.

​Learn more​ ▸

Gene Expression

The next evolution in qPCR for gene expression analysis
The new CFX Opus System puts you on the road to an integrated workflow for your modern lab. CFX Opus System is the next step in connectivity and instrument usability from your trusted partner in qPCR and gene expression.

​Learn more​ ▸

CFX Opus Real-Time PCR Detection Systems

​With improved thermal performance, an accurate optical shuttle system, and an easy-to-use interface with new connectivity options and features, your data will be more consistent than ever.

​Learn more​ ▸

Next-Generation Sequencing

Streamlining NGS workflows for maximum accuracy and efficiency 
Discover biologically relevant differences in more areas of the transcriptome with Bio-Rad's novel NGS solutions. Minimize your library preparation time in a streamlined workflow to answer the most complex biological questions.

​Learn more​ ▸

Whole Transcriptome RNA-Sequencing

​Enable transcriptome profiling for your cancer biomarker discovery with our RNA sequencing workflow.

​Learn more​ ▸

New Product: SEQuoia RiboDepletion Kit

Introducing a stand-alone, post-library depletion kit that eliminates rRNA and mt rRNA fragments while retaining rare and small transcripts. Combine with SEQuoia complete stranded RNA library kit to save time and money.

​Learn more​ ▸

Stain-Free Western Blotting

Faster results. Better data.​
Stain-Free Western Blotting workflow will significantly improve your results, by empowering you with actionable data at every stage in a third of the time. Enhance protein transfer efficiency with the Trans-Blot Turbo Transfer System. Improve accuracy and sensitivity when analyzing cancer biomarkers paired with the best-in-class ChemiDoc MP system.

​Learn more​ ▸

ChemiDoc MP Imaging System

The ChemiDoc MP system is feature-packed for imaging both gels and Western blots. It is designed to address multiplex fluorescence, chemiluminescence detection, stain-free imaging and gel imaging applications.

​Learn more​ ▸

Trans-Blot Turbo Transfer System

​The Trans-Blot Turbo Transfer System is a high-performance Western Blotting transfer system. It is designed to provide rapid gel-to-blot protein transfer in as little as 3 minutes.

​Learn more​ ▸

Cell Analysis

Rapid high color flow cytometry​
ZE5 Cell Analyzer is a high performance, automation-ready flow cytometer with the ideal combination of high-throughput screening and high color to identify cancer biomarkers faster.

​Learn more​ ▸

ZE5 Cell Analyzer

Innovative flow cytometer with flexible configurations to meet a broad range of experimental complexities and throughput needs — accessible for novice flow cytometry users yet versatile enough for the most experienced flow cytometry professionals.

​Learn more​ ▸

Scientific Presentations

Prognostic Biomarkers


1:30–5 PM   |   Section 31, #1

Takaaki Sasaki, Asahikawa Medical University, Japan

Longitudinal minimally invasive monitoring of resistance mutations in ALK rearranged lung cancer patients

1:30–5 PM   |   Section 32, #5

Zahra Haider, Umeå University, Sweden

UMAP—Personalized lung cancer monitoring platform

1:30–5 PM   |   Section 32, #10

Suha Naffar-Abu Amara, Kronos Bio, Inc.

Development of a liquid biopsy assay to longitudinally monitor changes in mutations’ allelic frequency in response to treatment with KB-0742

1:30–5 PM   |   Section 32, #14

Jennifer M. Wiggins, NYU Grossman School of Medicine

Development of a novel 5-plex copy number ddPCR assay for ctDNA analysis

Clinical Research in Special Populations/Supportive Care and Survivorship Research


1:30–5 PM   |   Section 30, #6

Kohei Hagiwara, St. Jude Children’s Research Hospital

Accelerated clonal hematopoiesis in survivors of childhood cancer: A report for the St. Jude Lifetime Cohort Study

Cell-Free DNA


1:30–5 PM   |   Section 31, #11

Sarah Tadhg Ferrier, Research Institute of the McGill University Health Centre, Canada

Characterizing treatment response in head and neck cancer through viral ctDNA quantification and fragment length

1:30–5 PM   |   Section 31, #14

Martyna Adamowicz, University of Edinburgh, United Kingdom

Longitudinal measurement of HPV copy number in cell free DNA predicts progression free survival in HPV positive oropharyngeal cancer

1:30–5 PM   |   Section 31, #18

Andrew Spencer, Monash University, Australia

Liquid biopsy for t(11;14)/blc2 identification in multiple myeloma

Preclinical and Clinical Pharmacology


9 AM –12:30 PM   |   Section 25, #2

Cara E. Bickers, Fate Therapeutics

Detection of genetically engineered iPSC-derived natural killer cells in blood and tissue

Circulating Tumor Cells and Prognostic Biomarkers


1:30–5 PM   |   Section 30, #3

Qiang Zhang, Northwestern University

A novel ESR1 mutation assay for single circulating tumor cell by application of DEPArray System and Digital Droplet PCR

Methods to Measure Tumor Evolution and Heterogeneity


1:30–5 PM   |   Section 14, #11

Prisca Bustamante, Research Institute of the McGill Health Centre, Canada

Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells

Risk Assessment, Biomarkers, Early Detection, and Screening


9 AM–12:30 PM   |   Section 2, #1

Dana Ruminski Lowe, LGC Clinical Diagnostics, Inc.

Reference materials for ctDNA-based measurable residual disease (MRD) assay development and validation

Hematological and Pediatric Malignancy and Sarcoma Treatment Resistance


9 AM–12:30 PM   |   Section 23, #5

Yanan Kuang, Dana-Farber Cancer Institute

BCL-2 G101V mutations develop in one-third of patients on continuous venetoclax

Identification of Molecular Targets


9 AM–12:30 PM   |   Section 24, #14

Sarah Heine, Navigate BioPharma Services, Inc.

Modular ddPCR assay design for highly sensitive single nucleotide variant detection




Presentation 5109

Bingsi Li, Burning Rock Biotech, China

Development of cfDNA reference standards for methylation-sequencing tests

Presentation 5110

Dennis J. O’Rourke, EMD Serono Research and Development Institute Inc.

Development and validation of a liquid biopsy assay with cerebrospinal fluid derived cell free DNA using droplet digital PCR for clinical applications

Presentation 5139

William C.S. Cho, Queen Elizabeth Hospital, China

Development of AR-V7 blood-based detection test by digital PCR in castration-resistant prostate cancer patients undergoing hormonal therapy

Presentation 5155

William C.S. Cho, Queen Elizabeth Hospital, China

Noninvasive detection of HER2 amplification in breast cancer with plasma DNA digital PCR

Presentation 5163

Sean Michael Boyle, Personalis, Inc.

A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimal residual disease at part per million resolution

Drug Discovery


Presentation 5323

Audrey Audetat, Biodesix, Inc.

Analytic and clinical validation of a new pan-cancer NGS liquid biopsy test for the detection of copy number variations, fusions/exon skipping, somatic variants and indels

Molecular Targets


Presentation 5400

Miguel Alfonso V. Principe, Lunenfeld-Tanenbaum Research Institute, Canada

Detection of satellite tumor cells in peritumoral edema in myxofibrosarcoma and undifferentiated pleomorphic sarcoma using targeted gene sequencing

Population Sciences


Presentation 5863

Dornell Pete, University of Washington

The ABID (Assessing the gut microbiota and Individual Diet) Study in the Navajo Nation

Bioinformatics and Computational Biology


Presentation 6171

Saurabh Parikh, Mission Bio Inc.

A single-cell solution for solid tumors to detect mutations and quantify copy number variations

Preclinical Immunotherapy


Presentation 6251

Elizabeth T. Andrews, Amgen Inc.

Evaluation of a dual-targeting BCMA-CS1 HLE BiTE molecule for multiple myeloma

microRNAs and Other Noncoding RNAs


Presentation 6285

Yuki Kaneko, Jichi Medical University, Japan

MicroRNA-217 affects tumor microenvironment and enhances the chemosensitivity of pancreatic cancer